AZ's Fasenra Gets Boost From Steroid-Sparing Data
Expansion Plans For Big-Selling Biologic
Executive Summary
The POTENTE trial demonstrated Fasenra’s impact in eliminating or reducing oral corticosteroid use for severe asthma patients, which should help AstraZeneca as it takes on GlaxoSmithKline’s rival IL-5 inhibitor, Nucala.